143 related articles for article (PubMed ID: 12679153)
41. The role of the abdominal visceral innervation and 5-hydroxytryptamine M-receptors in vomiting induced by the cytotoxic drugs cyclophosphamide and cis-platin in the ferret.
Hawthorn J; Ostler KJ; Andrews PL
Q J Exp Physiol; 1988 Jan; 73(1):7-21. PubMed ID: 3347698
[TBL] [Abstract][Full Text] [Related]
42. Management of cisplatin-induced delayed emesis.
Hesketh P
Oncology; 1996 Jun; 53 Suppl 1():73-7. PubMed ID: 8692555
[TBL] [Abstract][Full Text] [Related]
43. Reduced normogastric electrical activity associated with emesis: a telemetric study in ferrets.
Percie du Sert N; Chu KM; Wai MK; Rudd JA; Andrews PL
World J Gastroenterol; 2009 Dec; 15(48):6034-43. PubMed ID: 20027675
[TBL] [Abstract][Full Text] [Related]
44. The COX inhibitors indomethacin and meloxicam exhibit anti-emetic activity against cisplatin-induced emesis in piglets.
Girod V; Dapzol J; Bouvier M; Grélot L
Neuropharmacology; 2002 Mar; 42(3):428-36. PubMed ID: 11897121
[TBL] [Abstract][Full Text] [Related]
45. Differential action of domperidone to modify emesis and behaviour induced by apomorphine in the ferret.
Lau AH; Ngan MP; Rudd JA; Yew DT
Eur J Pharmacol; 2005 Jun; 516(3):247-52. PubMed ID: 15963978
[TBL] [Abstract][Full Text] [Related]
46. Drug treatment of chemotherapy-induced delayed emesis.
Tavorath R; Hesketh PJ
Drugs; 1996 Nov; 52(5):639-48. PubMed ID: 9118814
[TBL] [Abstract][Full Text] [Related]
47. Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone.
Kris MG; Pendergrass KB; Navari RM; Grote TH; Nelson AM; Thomas V; Ferguson BB; Allman DS; Pizzo BA; Baker TW; Fernando IJ; Chernoff SB
J Clin Oncol; 1997 May; 15(5):2135-8. PubMed ID: 9164228
[TBL] [Abstract][Full Text] [Related]
48. Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Italian Group for Antiemetic Research.
Support Care Cancer; 2000 May; 8(3):229-32. PubMed ID: 10789965
[TBL] [Abstract][Full Text] [Related]
49. 5-Hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis.
Costall B; Domeney AM; Naylor RJ; Tattersall FD
Neuropharmacology; 1986 Aug; 25(8):959-61. PubMed ID: 3774121
[TBL] [Abstract][Full Text] [Related]
50. Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles.
de Wit R; van den Berg H; Burghouts J; Nortier J; Slee P; Rodenburg C; Keizer J; Fonteyn M; Verweij J; Wils J
Br J Cancer; 1998 May; 77(9):1487-91. PubMed ID: 9652766
[TBL] [Abstract][Full Text] [Related]
51. Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin.
Mantovani G; Macciò A; Curreli L; Lampis B; Ghiani M; Bianchi A; Contu P
Oncol Rep; 1998; 5(1):273-80. PubMed ID: 9458381
[TBL] [Abstract][Full Text] [Related]
52. The interaction of dexamethasone with ondansetron on drug-induced emesis in the ferret.
Rudd JA; Bunce KT; Naylor RJ
Neuropharmacology; 1996 Jan; 35(1):91-7. PubMed ID: 8684601
[TBL] [Abstract][Full Text] [Related]
53. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
[TBL] [Abstract][Full Text] [Related]
54. Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin.
Kris MG; Cubeddu LX; Gralla RJ; Cupissol D; Tyson LB; Venkatraman E; Homesley HD
Cancer; 1996 Nov; 78(10):2193-8. PubMed ID: 8918414
[TBL] [Abstract][Full Text] [Related]
55. [The control of chemotherapy-induced nausea and vomiting].
Shinkai T; Saijo N; Sawamura N; Funaki U; Takahashi S; Yokoyama S; Fujita J; Futami H; Sasaki Y; Shimizu E
Gan No Rinsho; 1985 Jun; 31(7):779-91. PubMed ID: 3897622
[TBL] [Abstract][Full Text] [Related]
56. The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo.
Gandara DR; Harvey WH; Monaghan GG; Perez EA; Stokes C; Bryson JC; Finn AL; Hesketh PJ
Semin Oncol; 1992 Aug; 19(4 Suppl 10):67-71. PubMed ID: 1387253
[TBL] [Abstract][Full Text] [Related]
57. Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
Massidda B; Ionta MT
J Chemother; 1996 Jun; 8(3):237-42. PubMed ID: 8808724
[TBL] [Abstract][Full Text] [Related]
58. Antiemetic effect of dexamethasone on cisplatin-induced early and delayed emesis in the pigeon.
Tanihata S; Oda S; Nakai S; Uchiyama T
Eur J Pharmacol; 2004 Jan; 484(2-3):311-21. PubMed ID: 14744618
[TBL] [Abstract][Full Text] [Related]
59. Antiemetic effects of YM060, a potent and selective serotonin (5HT)3-receptor antagonist, in ferrets and dogs.
Kamato T; Miyata K; Ito H; Yuki H; Yamano M; Honda K
Jpn J Pharmacol; 1991 Nov; 57(3):387-95. PubMed ID: 1813664
[TBL] [Abstract][Full Text] [Related]
60. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.
J Clin Oncol; 1997 Jan; 15(1):124-30. PubMed ID: 8996133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
